Cardiff Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cardiff Oncology, Inc. (CRDF) on August 9, 2023, covering events occurring on August 8, 2023. The filing primarily addresses the elimination of specific series of convertible preferred stock and references the company's financial results for the second quarter ended June 30, 2023.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. Item 2.02 states that financial results for the second quarter ended June 30, 2023, were announced in a press release furnished as Exhibit 99.1, but the detailed metrics are not included in the body of this 8-K document.
Material Changes
On August 8, 2023, the Company filed a Certificate of Elimination with the Delaware Secretary of State. This action removed the designation of Series B, Series C, Series D, and Series E Convertible Preferred Stock from the Company's Amended and Restated Certificate of Incorporation. The following shares, which were previously designated but no longer issued and outstanding, were returned to the status of authorized but unissued shares:
- Series B: 8,860 shares
- Series C: 200,000 shares
- Series D: 154,670 shares
- Series E: 865,825 shares
Guidance, Outlook, and Risks
The filing does not contain specific guidance, outlook, management commentary, or risk factors within the text provided. It notes that the information regarding financial results in Item 2.02 is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other documents except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2023) for specific Q2 2023 financial metrics and operational highlights.
- Examine Exhibit 3.1 (Certificate of Elimination) for the full legal text regarding the removal of preferred stock designations.
- Verify the current authorized share count and capital structure following the elimination of the specified preferred stock series.